Intended for healthcare professionals

News

Research into treatments for mental illness is under threat

BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3747 (Published 14 June 2011) Cite this as: BMJ 2011;342:d3747

companies who stop research in Psychotropic drugs

Editor, Last year, AstraZeneca and GlaxoSmithKline announced the
cessation of research activity in the field of psychiatric drug
development (1). This put research into treatments for mental illness
under threat (2). It was thought there were many factors, amongst which,
that there is no incentive for research into mental illness drugs. As a
Royal College and its members, what should we do about these drug
companies who have stopped research in psychotropic drugs? I think we need
to boycott the activities of these companies. I wonder if, for example,
drug companies stopped research into drugs used in Cardiology, what would
we expect the Royal College of Physicians & its members to do?

References

1.Cowen PJ Has psychopharmacology got a future? The British Journal
of Psychiatry 2011; 198: 333-335

2.Wise J Research into treatments for
mental illness is under threat. BMJ 2011;342:doi:10.1136/bmj.d3747
(Published 14 June 2011)

Competing interests: No competing interests

23 June 2011
Abdul K Al-Sheikhli
Consultant Psychiatrist
CRHTT,Woodlands Centre for Acute Care,Sussex Partnership NHS Trust,St.Leonards on Sea